Is it Time to Dump Your Shares of Moderna?

After soaring to success in the early days of the COVID-19 pandemic, Moderna (MRNA 0.20%) experienced a reversal of fortune. The coronavirus vaccine maker has seen revenue plummet as demand for this flagship product -- Moderna's first to be approved -- has slipped. As a result, the stock fell out of favor with investors, leading to a decline of about 80% over the past three years.Since that time, the biotech company has delivered positive news, from the approval of a second product -- its respiratory syncyt ...